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Background/aim: We investigated the association of three IL-10 promoter single-nucleotide polymorphisms and altered IL-10 plasma
levels with the risk of head and neck cancer (HNC).
Materials and methods: Study subjects comprised 194 HNC patients [137 nasopharyngeal cancer (NPC) and 57 laryngeal
cancer (LC)], and 263 healthy controls. Genotyping of rs1800896 (-1082A>G), rs1800871 (-819C>T), and rs1800872 (-592A>C) IL10 variants was performed by real-time PCR; IL-10 levels were measured by enzyme amplified immuno sensitivity assay (EAISA).
Results: Carriage of rs1800896 A/A genotype was more frequent in the HNC and NPC cases, but was less frequent in the controls than
the LC patients. Significant differences in IL-10 levels were observed between the rs1800896A/G genotype-carrying NPC patients and
the controls. Positive association with NPC and LC was observed for rs1800871C/C, and carriage of rs1800872A/A genotype, and A
allele were associated with higher risk of HNC and NPC, but not LC. GT rs1800896-rs1800871 haplotype was more frequent among
the HNC and NPC patients than the controls in contrast to GC haplotype, which has a protective effect. Positive association was found
between TA haplotype and LC.
Conclusion: Our results demonstrate that IL-10-1082, IL-10-819, and IL-10-592 variants, and haplotypes GC and GT constitute
biomarkers for early detection of HNC, especially NPC subtype. IL-10 -819T/C and TA haplotype may be used as biomarkers for early
detection of LC.
Keywords: Head and neck cancer, interleukin-10, laryngeal cancer, nasopharyngeal cancer, Tunisia

1. Introduction
Recent evidence supports increased head and neck
cancer (HNC) incidence worldwide, with estimated
400,000–600,000 new cases per year, and 223,000–
300,000 annual deaths (1,2). HNC arises from malignant
transformation of upper respiratory tract epithelial cells
(3), and nasopharyngeal carcinoma (NPC) and laryngeal
cancer (LC) are the most prevalent forms of HNC (4).
Although NPC and LC are anatomically and histologically
related, they differ in the pathogenesis, biology, treatment,
mortality, and morbidity, as well as geographic and
ethnic incidence (5–7). HNCs are multifactorial
malignancies, which are influenced by environmental,
viral, immunogenetic, and lifestyle risk factors (8–10).

However, few studies addressed the implication of these
factors in the variability of and the relative susceptibility
to NPC and LC within different populations. Several
reports documented the contribution of altered balance
of proinflammatory and antiinflammatory mechanisms
in HNC development, but with mixed outcome (11,12).
As an immunosuppressive cytokine, interleukin-10 (IL10) was described as a key player in the pathogenesis and
progression of NPC and related malignancies (13).
Located on chromosome 1 (1q31–q32), human IL10 gene consists of five exons and four introns (14),
and several single nucleotide polymorphisms (SNP)
were identified in IL-10 promoter region (15). Of these,
rs1800896 (-1082A/G), rs1800871 (-819C/T), and
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rs1800872 (-592A/C) were the most investigated (16,17).
Previous studies documented the association of these IL10 variants with cancers (18–20), including NPC (21), but
with inconclusive findings, and an ethnic contribution to
this association appeared likely. As these IL-10 promoter
variants rs1800896 (-1082 A/G), rs1800871(-819 C/T), and
rs1800872 (-592 A/C) modulate IL-10 serum levels, and
hence HNC susceptibility, the purpose of the present study
was to evaluate these three IL-10 promoter polymorphisms
and plasma IL-10 levels as potential biomarkers for HNC.
2. Materials and methods
2.1. Study subjects
Between November 2012 and October 2015, 194 HNC
cases were consecutively recruited from Salah Azaiz
Oncology Institute (SAI, Tunisia). All HNC cases
originated from North Tunisia, of whom 137 presented
with histologically confirmed nondifferentiated carcinoma
of nasopharyngeal type (UCNT), and the remaining 57
presenting with histologically confirmed squamous cell
carcinoma (SCC) of laryngeal type. Cancer diagnosis
was established by clinical and biopsy examination, and
confirmed by an SAI senior pathologist. Clinical data were
obtained by unified questionnaire, personal interviews,
and review of case records. All subjects were asked to
sign a consent form, agreeing to participate in the study,
after all institutional ethical requirements were met. The
control group consisted of 263 unrelated blood donors,
who reported no personal or family history of cancer, or
other chronic illness.
2.2. DNA extraction
Peripheral blood samples (5 mL) of patients and control
subjects were collected in EDTA-containing tubes.
Genomic DNA was extracted from buffy coat layer
using QIAamp® DNA blood Mini Kit, according to the
instruction of the manufacturer (Qiagen GmbH, Hilden,
Germany). DNA was stored in nuclease-free water at 4 °C
pending analysis.
2.3. IL-10 plasma levels
Blood samples were collected from patients and controls
in plain tubes. Plasma was separated by centrifugation at
2000 ×g for 15 min at 4 °C, and stored as 250 µL aliquots
−80 °C pending analysis. IL-10 levels were measured using
a commercial EAISA kit, according to the manufacturer’s
instructions (DIA source Immuno Assay, Louvain-laNeuve, Belgium). The ELISA reader-controlling software
(SoftMax) was used in processing raw absorbance values
into a standard curve, from which IL-10 concentrations
(pg/mL) were obtained.
2.4. IL-10 genotyping
The three IL-10 gene polymorphisms studied, i.e.
rs1800872, rs1800871, and rs1800896, were selected due to
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their minor allele frequency (MAF) of >5% in Caucasians,
and previous association with HNC development. IL-10
genotyping was performed using the allelic (VIC- and
FAM-labeled) discrimination method. Assay-on-demand
TaqMan genotyping assays were ordered from Applied
Biosystems (Foster City, CA, USA): C_1747363_10
(rs1800872),
C_1747362_10
(rs1800871),
and
C_1747360_10 (rs1800896). The reaction was performed
in 6 µL volume on StepOne Plus real-time PCR systems,
according to the manufacturer’s instructions (Applied
Biosystems). Replicate blinded quality control samples
were included to assess genotyping reproducibility; the
concordance was >99%.
2.5. Statistical analysis
Statistical analysis was performed with R software for
windows and R studio program (www.rstudio.com),
version 3.2.3. The characteristics of the study subjects
were reported as mean for age, medians for IL-10 level,
and relative frequencies for sex, tobacco and alcohol
consumption, and histological type. The effect of IL-10
polymorphisms on IL-10 plasma levels, as well as HNC,
NPC, and LC were evaluated by setting homozygous major
allele genotype as reference; subsequent analyses were
performed using one-way ANOVA. Chi-quare test was
used in comparing categorical data and Fisher exact test
for low number. Receiver operating characteristic (ROC)
curve was used to determine sensitivity and specificity;
P < 0.05 was considered statistically significant. Linkage
disequilibrium and haplotype reconstruction were
performed using Haploview 4.2 (www.broadinstitute.
org) software and SNPstats (www.bioinfo.iconcologia.net/
snpstats/), which also tested for departure from Hardy–
Weinberg equilibrium (HWE).
2.6. Ethics
The study protocol was approved by the Ethics Committee
of Salah Azeiz Oncology Institute in Tunis, Tunisia.
3. Results
3.1. Study participants
Table 1 summarizes the demographic and clinical
characteristics of HNC patients and control subjects. Study
subjects comprised 194 patients (137 with NPC, mean age
48 years, and 57 with LC, mean age 46.31 years), and 263
control subjects (mean age 49.96 years). The median IL10 plasma level was slightly lower in the HNC patients
[2.25 (0.003–39.45) pg/mL than the control subjects [4.65
(1.79–10.73) pg/mL], but was not statistically significant
(P = 0.34).
3.2. Association between IL-10 polymorphisms and
HNC
The distribution of IL-10 -1082A/G, -819C/T, and -592C/
A genotypes did not deviate from HWE (P > 0.05). Table
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Table 1. Clinical characteristics of HNC, NPC, and LC patients and the healthy controls.
Characteristics
Female/male

Controls HNC
OR1 (95% CI)
n = 263 n = 194
171/92 45/149 6.154 4.077–9.431

NPC
LC
OR2 (95% CI)
OR3
(95% CI)
n=137
n = 57
39/98 4.671 3.001–7.383 6/51 15.799 7.032-42.367

< 0.001

Age (years)

49.96

48

0.54

49.23

0.995 0.981–1.010

1.022–1.077

P-value

0.977 0.960–0.993 46.31

1.049

31.420 13.786–85.169 < 0.001

Tobacco

56/207

126/68 6.849 4.539–10.467 75/62

4.471 2.870–7.032 51/6

Alcohol

39/224

76/118 3.669 2.382–5.821

44/93

2.717 1.660–4.470 32/25 7.352

3.963–13.858 < 0.001

UCNT

NA

137

-

-

137

-

-

-

-

-

-

SCC

NA

57

-

-

-

-

-

57

-

-

-

2.250

0.969 0.908–1.047

2.250

0.944 0.863–1.026 3.120

1.008

0.917–1.129

0.34

Histology

IL-10 level (pg/mL) 4.650

HNC: head and neck cancer; n: number of subjects; NPC: nasopharyngeal carcinoma; LC: laryngeal cancer; OR1: odds rate between
the HNC patients and the controls, OR2 : odds rate between the NPC patients and the controls; OR3: odds rate between the LC
patients and the controls; CI: confidence interval; P-value: one way ANOVA; Age: per year; Tobacco: smokers/nonsmokers; Alcohol:
drinkers/nondrinkers; UCNT: undifferentiated carcinoma nasopharynx type; SCC: squamous cell carcinoma; NA: not applicable;
IL-10 level : (pg/mL).
Table 2. Association between IL-10 genotypes and the development of head and neck, nasopharyngeal and laryngeal cancers.
SNPs

HWE P1

rs1800896

0.253

OR

A/A

reference 1.00

A/G

0.028

1.58 [1.05–2.40]

G/G

0.064

0.57 [0.31–1.02]

G

0.777

0.94[0.69–1.28]

rs1800871

0.000

P2

OR

reference

1.00

0.007

1.88 [1.18–3.03]

0.391

0.74 [0.38–1.42]

0.978

P2*

P3

OR

P3*

reference 1.00
0.767

1.09 [0.59–2.02] 0.036

0.020

0.28 [0.08–0.78]

1.01[ 0.72–1.42]

0.3638

0.77[0.48– 1.25]

reference

1.00

reference 1.00

0.936

0.98 [0.63–1.52]

0.016

2.50 [1.16–5.44]

0.472

0.001

0.707

C/C

reference 1.00

C/T

0.232

1.26 [0.85–1.87]

T/T

0.005

2.67 [1.32–5.59]

0.159

1.27[0.92–1.76]

T
rs1800872

P1*

0.019

0.006

2.35 [1.27–4.48] 0.009

0.021

3.33 [1.07–9.50]

1.16[0.80–1.67]

0.087

1.54[0.96– 2.47]

reference 1.00

0.042

0.830

C/C

reference 1.00

reference

1.00

C/A

0.998

1.00 [0.67–1.47]

0.384

0.82 [0.52–1.27]

A/A

0.009

2.51 [1.24–5.24]

0.017

2.45 [1.15–5.32]

A

0.023

1.15 [0.83–1.58]

0.013

1.08 [0.75–1.55]

0.026

0.016

0.139

1.58 [0.86–2.97] 0.118

0.060

2.70 [0.87–7.61]

0.291

1.31 [0.82–2.11]

SNP: single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; Significant associations P < 0.05 are indicated in bold;
P1 value: chi-square test between the HNC patients and the controls; P1*: one-way ANOVA between the HNC and the controls; P2
value: chi-square test between the NPC patients and the controls; P2*: one-way ANOVA between the NPC patients and the controls;
P3 value: chi-square test between the LC patients and the controls; P3*: one-way ANOVA between the LC patients and the controls.

2 lists the frequencies of the genotype profiles of the tested
SNPs, first between the HNC patients and controls, second
between the NPC patients and the controls, and third
between the cases with LC and the controls. Univariate
and multivariate analyses confirmed significant differences
between the HNC or NPC patients and the controls in the

distribution of the three tested IL-10 SNPs. Significant
differences were observed between the LC patients and the
controls in the distribution of rs1800896 (-1082A>G) and
rs1800871 (-819C>T).
The distribution of rs1800896 A/A genotype was
significantly different between HNC cases and control
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subject [P < 0.001, OR (95% CI) = 1.58 (1.05–2.40)], and
between the NPC patients and controls [P = 0.001, OR
(95% CI) = 1.88 (1.18–3.03)]. Negative association was
observed for this genotype between th LC cases and the
controls [P = 0.036, OR (95% CI) = 0.28 (0.08–0.78)].
A positive association was noted in the association of
rs1800871 C/C genotype with NPC [P = 0.042, OR (95%
CI) = 2.50 (1.16–5.44)] and LC [P = 0.009, OR (95% CI)
= 3.33 (1.07–9.50)] susceptibility. In addition, rs1800872
A/A genotype was associated with higher risk of HNC [P =
0.026, OR (95% CI) = 2.51 (1.24–5.24)] and NPC P = 0.016,
OR (95% CI) = 2.45 (1.15–5.32)], but not LC. In addition,
rs1800872 minor (A) allele frequency was associated with
higher risk of HNC and NPC.
3.3. Plasma IL-10 level analysis
Plasma IL-10 levels in the HNC patients and the control
subjects were next determined, and ROC analysis was performed to assess sensitivity and specificity. The area under
the curve was 0.72 (Figure 1), suggesting insufficient sensitivity and specificity of EAISA determinations. HNC cases
and controls were stratified according to specific IL-10
genotypes, and plasma IL-10 concentrations were determined for specific IL-10 genotypes in the patients and the
controls. Results from Figure 2 and Table 3 demonstrate a
significant difference in IL-10 plasma levels between -1082
A/G (rs1800896) NPC patients and control subjects genotype carriers (P = 0.023).
3.4. Haplotype analysis
Haploview analysis revealed high linkage disequilibrium
(LD) between rs1800871 and rs1800896 (0.72), but weak
LD between rs1800872 and the two other SNPs (LD = 0.46
and 0.45). IL-10 haplotypes were constructed based on
rs1800871 and rs1800896 minor allele frequencies, with
four haplotypes (with a frequency >1%) were found. Results
from Table 4 demonstrated enrichment of the two minor
alleles GT haplotype among the HNC and NPC patients
than the controls, thereby assigning disease susceptibility
nature to this haplotype [P = 0.002, OR (95% CI) = 2.98
(1.48–6.02); P < 0.001, OR (95% CI) = 3.62 (1.75–7.48)],
respectively. The distribution of the other haplotypes was
comparable between the HNC and the controls. However,
GC haplotype appears to be protective of HNC [P = 0.038,
OR (95% CI) = 0.69 (0.49–0.98)] and NPC subtype [P =
0.021, OR (95% CI) = 0.64 (0.43–0.95)]. Furthermore, a
positive association was found between TA haplotype and
LC [P = 0.03, OR (95% CI) = 2.25 (1.32–3.83)].
4. Discussion
Increasing evidence implicated imbalance of pro- and
antiinflammatory cytokines in the persistence of local
inflammation in HNC patients, including NPC and LC, of
which IL-10 was hypothesized to be a key determinant in
HNC growth (22,23). Recent studies suggested that genetic
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Figure 1. Sensitivity and specificity of IL-10 level
measurment. Receiver operating characteristic (ROC)
curve on binary logistic regression and discriminant
classification analysis for the HNC and the control groups.
Sensitivity and specificity were assessed by measuring the
area under the curve.

Figure 2. Level of IL-10 in the HNC, NPC, and LC
patients and the controls AG genotype of rs1800896.
HNC: head and neck cancer; NPC: nasopharyngeal
cancer; LC: laryngeal cancer; Ctrl: control. NS: not
significant.
Table 3. Genotype distribution and serum IL-10 levels.
IL-10 level (pg/mL)
SNP/genotype

Cases

Controls

Means ± SD

Means ± SD

AA

2.46 ± 2.47

4.06 ± 2.18

0.1211

AG

3.59 ± 6.41

4.44 ± 2.78

0.0231

GG

3.68 ± 4.05

6.05 ± 2.38

0.1552

P-value

IL-10-1082 A/G

AA vs. AG+GG

0.7923

btained using the Mann–Whitney U test, 2obtained using the
Student’s t-test, 3comparison between IL-10 levels in the carriers
and those in the noncarriers.
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Table 4. Two-loci IL-10 haplotype distribution in head and neck, nasopharyngeal and laryngeal cancer cases and controls.
HNC

NPC
OR (95% CI)

LC

Haplotype

Cases

Controls P

AC

0.379

0.352

–

GC

0.283

0.387

0.038 0.69 (0.49–0.98) 0.288 0.0219 0.64 (0.43–0.95) 0.294

–

AT

0.229

0.225

0.81

0.03 2.25 (1.32–3.83)

GT

0.108

0.034

0.002 2.98 (1.48–6.02) 0.131 <0.001 3.62 (1.75–7.48) 0.030

1

Cases P

2

0.397 _
0.95 (0.64–1.43) 0.182 0.12

OR (95%CI)

Cases

P3

0.311

0.67 1.12 (0.66–1.89)

0.68 (0.42–1.11) 0.364

OR (95% CI)

0.83 1.20 (0.22–6.49)

HNC: head and neck cancer; n: number of subjects; NPC: nasopharyngeal carcinoma; LC: laryngeal cancer. 1: two-locus
rs180087-rs1800896 haplotype; underlined bold indicates minor allele; 2: nasopharyngeal cancer versus controls; 3: laryngeal
cancer versus controls

polymorphisms in pro- and antiinflammatory cytokines
contribute to the pathogenesis of several malignancies,
including HNC (24,25). This prompted the speculation that
cytokine gene variants may serve as potential biomarkers
for NPC detection, especially in the early stages. This
incited us to investigate the possible relationship between
common IL-10 promoter variants -1082A/G (rs1800896),
-819C/T (rs1800871), and -592C/A (rs1800872), and the
risk of HNC in Tunisians.
A positive association was observed between -1082A/
G (rs1800896) polymorphism and HNC and NPC risk.
This was in agreement with two recent metaanalyses. The
first one carried out on nine studies involving 2258 HNC
patients and 2887 control subjects reported an OR of 1.64
when the -1082A/G genotype carriers were compared
to those of -1082A/A (24). The second metaanalysis,
including four NPC case-control studies, revealed that
carriage of -1082A/G and -1082A/A genotypes were
associated with 1.77-fold elevated risk of NPC, when
compared with the homozygous G/G genotype (21).
Collectively, this supports the notion that -1082A/G IL10 variant constitutes a risk factor for HNC and NPC.
On the other hand, a negative association of rs1800896
A/A genotype was observed between the LC patients and
the controls, suggesting a protective effect of this variant
against LC development.
IL-10 rs1800871 C/C genotype was associated
with 2.5-fold and 3.33-fold higher risk of NPC and LC
development, respectively, and carriers of rs1800872
A/A genotype were at 2.5-fold higher risk for HNC and
NPC but not LC. In contrast, no statistically significant
association was detected between these two IL-10 variants
and HNC and NPC according to the results of these two
recent metaanalyses (21,24).
While the tested IL-10 variants were linked with altered
IL-10 secretion in rheumatoid arthritis (17), and gastric
inflammation (26), few studies investigated the association
between IL-10 genotypes and IL-10 levels in HNC. To

the best of our knowledge, this was the first study that
examined the association between IL-10 genotypes and
IL-10 levels in HNC. Although the three tested variants
were previously linked with altered IL-10 secretion, our
findings indicate that only rs1800896 was associated with
reduced IL-10 levels. These points to the contribution of
HNC-associated factors in regulating the IL-10 secretion.
Haploview analysis revealed high LD between
rs1800871 and rs1800896, but weak LD between rs1800872
and the two other IL-10 variants. Of the four obtained
haplotypes, GT (minor) and GC were positively associated
with HNC and NPC, but not with LC. In addition, AT
haplotype was positively associated with LC but not with
NPC. The contradictory results obtained for LC and
NPC are explained by the different etiologies of these
HNCs. This is supported by our recent study evaluating
the effect of eight VEGF-A polymorphisms on LC and
NPC susceptibility, which revealed that none of the tested
variants significantly influenced LC risk contrary to their
association with NPC, further confirming that these HNCs
have different etiologies (27).
5. Conclusion
The present findings showed that IL-10 rs1800896,
rs1800871, and rs1800872 variants, along with specific
(2-loci) haplotypes contribute to the development of
NPC. This suggests a possible role for these variants as
biomarkers for early detection of HNC and especially the
NPC subtype. However, IL-10 rs1800871 and AT haplotype
may be used for detection of subjects at higher risk of LC.
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